First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer

First Patient Enrolled in Phase 1/2 Trial for Recurrent Ovarian Cancer
The first patient has been dosed in a Phase 1/2 trial assessing OncoQuest‘s anti-CA125 antibody oregovomab in combination with Opdivo (nivolumab) in women with recurrent ovarian cancer. The ORION-01 trial (NCT03100006), which is currently enrolling participants, is being conducted at the National Cancer Centre in Singapore (NCCS). Dr. Tira Tan is leading the study, and Prof. John

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *